000044809 000__ 00735nam\a2200313\i\4500
000044809 001__ 44809
000044809 003__ SzGeWIPO
000044809 005__ 20240708150137.0
000044809 006__ m\\\\eo\\d\\\\\\\\
000044809 007__ cr bn |||m|||a
000044809 008__ 220120s2022\\\\enk\\\\\o\\\\\000\0\eng\d
000044809 022__ $$aOnline: 2632-8550
000044809 040__ $$aSzGeWIPO$$beng$$erda$$cSzGeWIPO$$dCaBNVSL
000044809 041__ $$aeng
000044809 24500 $$aPermission to Use a COVID-19 Drug in the Interest of Public Health /
000044809 264_1 $$a[Oxford, England] :$$bOxford University Press (OUP),$$c2022
000044809 300__ $$a1 online resource (pages 37-41)
000044809 337__ $$acomputer$$2rdamedia
000044809 4901_ $$aGRUR International,$$x2632-8550 ;$$v71, 1, 2022
000044809 542__ $$fhttps://academic.oup.com/grurint/article/71/1/37/6364527
000044809 588__ $$aCrossref
000044809 590__ $$aPublished online: 06-Sep-21
000044809 650__ $$aIntellectual Property Rights
000044809 7731_ $$tGRUR International$$wGRUR
000044809 830_0 $$aGRUR International ;$$v71, 1, 2022.
000044809 85641 $$uhttps://academic.oup.com/grurint/article/71/1/37/6364527$$yonline version
000044809 904__ $$aJournal article
000044809 980__ $$aGRUR